)
Clinical toxicology is a complex science, and we know that choosing the right drug test can be challenging.
Test options for over 200 drug compounds
Presumptive, presumptive with reflex to definitive, and definitive testing (when possible)
Choice of individual drug classes by mixed methodologies as single tests, or along with others as part of a panel
Confirmatory drug class testing and analysis for those performing in-house drug screening
Blood and oral fluid test options for patients who are unable to provide urine samples
Consolidated reports with results and methodology-specific considerations
Definitive drug testing
Are you performing in-office drug screening? Labcorp’s ToxAssure Flex portfolio includes direct order confirmation tests for unequivocal determination of drug identification and quantitation.1 Our confirmation tests can be ordered individually to confirm targeted drugs (e.g., specific drug results from in-office screening).
%20copy.png)
?fmt=webp)
In addition to standard validity testing of creatinine, pH and specific gravity, a robust series of normal human urinary biomarkers are monitored to distinguish human urine from synthetic urine products.
?fmt=webp)
Our cumulative reports, available for ToxAssure Flex profiles and individual drug confirmations, track unexpected results based on reported medications and illicit drugs. Easily monitor and improve trends with our convenient report format, facilitating review of patient results and medication use over time.
?fmt=webp)
With direct, toll-free access to certifying scientists, you can engage in one-on-one consultations about test results and toxicology questions. For test menu inquiries, add-on or test change requests, results status and interpretation and technical discussion of patient-specific drug test results
Labcorp’s ToxAssure, ToxAssure Flex, and MAT testing results are normalized to the creatinine concentration in that urine sample. This approach allows for addressing the variability in drug concentrations due to the hydration status of the patient at the time of collection.
Immunoassay screening tests detect the presence of a class of drugs compared with confirmatory testing performed by gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/tandem mass spectrometry (LC/MS-MS) for unequivocal determination of drug identification and quantification.
There are several factors such as screening thresholds and drug cross-reactivity which may account for discordance between immunoassay and confirmation testing results. You can reference our definitive testing resource (L14987-0123-3) or contact our clinical drug testing support team (877-474-5767/clinicaldrugtesting@labcorp.com) for additional information.
See our drug detection range reference here (L686961-1023-1).
Yes, MDMA is included in our amphetamines drug class.
Our specimen validity testing identified this specimen as lacking normal urinary biomarkers or containing compounds found in synthetic urine that are not present in normal human urine.
